News about Global Pharma

Integral Molecular Launches Ready Reporter Virus Kit for 10x Faster Virus Neutralisation Testing

Integral Molecular Launches Ready Reporter Virus Kit for 10x Faster Virus Neutralisation Testing

RRVs work by instantaneous detection of viral entry using a fluorescence-based readout. This rapid, safe and simple assay enables automatable workflows that can be performed in a standard laboratory setting.

Global Pharma | 14/10/2025 | By Dineshwori 120

Cumberland Pharmaceuticals Expands Vibativ Access Through Premier Group Purchasing Agreement

Cumberland Pharmaceuticals Expands Vibativ Access Through Premier Group Purchasing Agreement

American specialty pharmaceutical company Cumberland Pharmaceuticals has announced that its potent antibiotic Vibativ (telavancin) has been added to a national group purchasing agreement with Premier, a leading US healthcare improvement company.

Global Pharma | 14/10/2025 | By Dineshwori 225

South Korea's GC Biopharma Secures CMO Rights for Curevo's Shingles Vaccine

South Korea's GC Biopharma Secures CMO Rights for Curevo's Shingles Vaccine

South Korean biopharmaceutical company GC Biopharma has signed a contract manufacturing agreement with Curevo Vaccine to produce amezosvatein (development name: CRV-101), a recombinant shingles vaccine currently under clinical development.

Global Pharma | 13/10/2025 | By Dineshwori 288

Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025

Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025

The data to be presented span Merck’s broad HIV portfolio, including investigational therapies for both treatment and prevention. The presentations will feature new clinical results from Phase 1, 2, and 3 studies evaluating the efficacy, safety, and pharmacokinetics of the company’s next-generation antiviral candidates.

Global Pharma | 13/10/2025 | By Dineshwori 277

Chugai Pharma concludes licence agreement with Roche for CT-388

Chugai Pharma concludes licence agreement with Roche for CT-388

Chugai Pharmaceutical has signed a licensing deal with F. Hoffmann-La Roche for CT-388, a long-acting GLP-1/GIP receptor agonist for obesity and type-II diabetes, granting Chugai exclusive development and marketing rights in Japan.

Global Pharma | 11/10/2025 | By Dineshwori 589

Johnson & Johnson MedTech Launches CORE-VA Registry to Advance Ventricular Arrhythmia Care

Johnson & Johnson MedTech Launches CORE-VA Registry to Advance Ventricular Arrhythmia Care

Johnson & Johnson MedTech, in collaboration with the Heart Rhythm Clinical and Research Solutions, has unveiled a new initiative aimed at improving outcomes for patients with life-threatening heart rhythm disorders.

Global Pharma | 11/10/2025 | By Dineshwori 254

AstraZeneca, Trump Administration Seal Historic Agreement to Make Medicines More Affordable for Americans

AstraZeneca, Trump Administration Seal Historic Agreement to Make Medicines More Affordable for Americans

AstraZeneca has announced a historic agreement with President Donald Trump’s administration to lower the cost of prescription medicines for American patients while strengthening the nation’s biopharmaceutical innovation base.

Global Pharma | 11/10/2025 | By Dineshwori 179

Shuttle Pharmaceuticals Signs LOI to Acquire Molecule.ai in USD 10 Million Deal

Shuttle Pharmaceuticals Signs LOI to Acquire Molecule.ai in USD 10 Million Deal

US-based specialty pharmaceutical company Shuttle Pharmaceuticals Holdings has signed a non-binding Letter of Intent (LOI) to acquire Molecule.ai, an advanced artificial intelligence firm revolutionising drug discovery and development.

Global Pharma | 10/10/2025 | By Dineshwori 302

Lonza Receives Swissmedic Approval for Highly Potent Biologics Drug Product Filling Line in Stein (CH)

Lonza Receives Swissmedic Approval for Highly Potent Biologics Drug Product Filling Line in Stein (CH)

Lonza has received Swissmedic approval for its new state-of-the-art aseptic filling line in Stein (CH), designed for biologics and highly potent products, including antibody-drug conjugates (ADCs).

Global Pharma | 10/10/2025 | By Dineshwori 200

Novo Nordisk to Acquire Akero Therapeutics Alongside Promising MASH Therapy Efruxifermin

Novo Nordisk to Acquire Akero Therapeutics Alongside Promising MASH Therapy Efruxifermin

Danish pharma giant Novo Nordisk has signed a definitive agreement to acquire Akero Therapeutics, a San Francisco-based clinical-stage biopharmaceutical company focused on developing innovative therapies for serious metabolic diseases.

Global Pharma | 10/10/2025 | By Dineshwori 312

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members